Figure 5
Effects of orobol on HFD-induced obesity in C57BL/6J mice (A) The photographs of the C57BL/6J mice at autopsy showed fat mass reduced by orobol treatment. (B) Orobol treatment for 23 weeks alleviated HFD-induced weight gain in C57BL/6 J mice. (C–E) Oorobol decreased epididymal fat, retroperitoneal fat, and perirenal fat masses. (F) Orobol has no significant effect on subcutaneous fat mass. (G) Caloric intake was unaffected by orobol (10 mgkg−1 BW). Values are expressed as means ± SEM. The sharps (# or ##) indicate a significant difference between the control group and the group treated with HFD (p < 0.05 or p < 0.01). The means marked with ‘*’ indicate significantly different compared to the group treated with HFD (p < 0.05).
